官网6800元，900元竟能买到同款？人气医美产品陷真假迷局

Core Viewpoint - The article highlights the rapid growth of the medical beauty market, particularly focusing on the product "Wei Yi Mei" from Jinbo Biotechnology, while also exposing the rampant issues of counterfeit products and unregulated practices within the industry [3][4][12]. Group 1: Product Overview - "Wei Yi Mei" is a flagship product of Jinbo Biotechnology, leveraging recombinant collagen technology, and has seen significant sales growth from 25,000 bottles in 2021 to 576,000 bottles in 2023, maintaining over 300% growth [3]. - The global sales of the first injectable recombinant humanized collagen freeze-dried fibers have surpassed 2 million units [3]. Group 2: Market Dynamics - The retail market size for recombinant collagen medical beauty injections in China reached 4.3 billion yuan in 2023, accounting for 6.4% of the total medical beauty injection market, with projections to grow to 14.3 billion yuan by 2027 [4]. - The retail market for recombinant collagen medical dressings also reached 11 billion yuan in 2023 [4]. Group 3: Industry Issues - The article reveals that the market is plagued by counterfeit products, with only 35% of medical beauty injectables in circulation being genuine, leading to over 30% of consumer complaints related to product quality [12]. - Numerous unauthorized medical institutions are offering services related to "Wei Yi Mei," often at prices significantly lower than the official retail price, which raises concerns about product authenticity [8][10]. Group 4: Regulatory Concerns - The article emphasizes the need for consumers to recognize "regular doctors, regular institutions, and regular products" as a defense against medical beauty risks [10]. - The rise of "medical beauty fast-track training classes" has contributed to the proliferation of unqualified practitioners, further endangering consumer safety [16][17].